A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09

详细信息    查看全文

• 作者：Ki Hyeong Lee ; Ji-Yeon Kim ; Moon Hee Lee ; Hye Sook Han…
• 关键词：Chemotherapy ; induced neutropenia ; Breast cancer ; Pegylated G ; CSF ; Pegteograstim ; Prophylaxis
• 刊名：Supportive Care in Cancer
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：24
• 期：4
• 页码：1709-1717
• 全文大小：600 KB
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Oncology
  Nursing
  Nursing Management and Research
  Pain Medicine
  Rehabilitation Medicine
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1433-7339

文摘

Purpose Pegylated granulocyte-colony-stimulating factor (G-CSF) is frequently used to prevent febrile neutropenia (FN) in patients undergoing chemotherapy with a high risk of myelosuppression. This phase II/III study was conducted to determine the adequate dose of pegteograstim, a new formulation of pegylated G-CSF, and to evaluate the efficacy and safety of pegteograstim compared to pegfilgrastim.